Last reviewed · How we verify

Morphine plus Ketamine — Competitive Intelligence Brief

Morphine plus Ketamine (Morphine plus Ketamine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combined with NMDA receptor antagonist. Area: Pain Management.

phase 3 Opioid analgesic combined with NMDA receptor antagonist Mu-opioid receptor (morphine); NMDA receptor (ketamine) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Morphine plus Ketamine (Morphine plus Ketamine) — University of California, San Francisco. Morphine and ketamine together provide analgesia through complementary pathways: morphine acts as an opioid receptor agonist while ketamine blocks NMDA receptors, potentially reducing opioid tolerance and enhancing pain relief.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Morphine plus Ketamine TARGET Morphine plus Ketamine University of California, San Francisco phase 3 Opioid analgesic combined with NMDA receptor antagonist Mu-opioid receptor (morphine); NMDA receptor (ketamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combined with NMDA receptor antagonist class)

  1. University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Morphine plus Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/morphine-plus-ketamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: